Testicular Cancer: Seminoma

Overview

Journal BMJ Clin Evid

Specialty General Medicine

Date 2009 May 21

PMID 19454048

Citations 2

Authors

Richard David Neal

Nicholas Stuart

Clare Wilkinson

Affiliations

Soon will be listed here.

Abstract

Introduction: More than half of painless solid swellings of the body of the testis are malignant, with a peak incidence in men aged 25-35 years. About half of testicular cancers are seminomas, which tend to affect older men and have a good prognosis.

Methods And Outcomes: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of treatments in men with stage 1 seminoma (confined to testis) who have undergone orchidectomy? What are the effects of treatments in men with good-prognosis non-stage 1 seminoma who have undergone orchidectomy? What are the effects of maintenance chemotherapy in men in remission after orchidectomy and chemotherapy for good-prognosis non-stage 1 seminoma? What are the effects of treatments in men with intermediate-prognosis seminoma who have undergone orchidectomy? We searched: Medline, Embase, The Cochrane Library and other important databases up to April 2006 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).

Results: We found 27 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.

Conclusions: In this systematic review we present information relating to the effectiveness and safety of the following interventions: adjuvant irradiation (20 Gy in 10 fractions to paraaortic area, 30 Gy in 15 fractions to paraaortic area and iliac nodes), chemotherapy (maintenance, adjuvant, single-agent carboplatin, three or four cycles, different number of cycles of adjuvant, using bleomycin added to vinblastine plus cisplatin, using etoposide plus cisplatin with or without bleomycin, adding higher doses to a two-drug chemotherapy regimen using cisplatin or vinblastine), radiotherapy (adjuvant, different drug combinations, 30-36 Gy in 15-18 fractions), surveillance.

Citing Articles

The timing of introduction of pharmaceutical innovations in seven European countries.

Westerling R, Westin M, Mckee M, Hoffmann R, Plug I, Rey G J Eval Clin Pract. 2014; 20(4):301-10.

PMID: 24750393 PMC: 4282430. DOI: 10.1111/jep.12122.

Metastatic seminoma and grade 1 follicular lymphoma presenting concurrently in a supraclavicular lymph node: a case report.

Jacobsen E, Chen J, Schurko B, Benson C, Oh W Cases J. 2009; 2:7273.

PMID: 19918516 PMC: 2769346. DOI: 10.4076/1757-1626-2-7273.

References

van de Wiel H, Hoekstra H, Sleijfer D, van Driel M, van Basten J, Schraffordt Koops H . Sexual functioning after treatment for testicular cancer--review and meta-analysis of 36 empirical studies between 1975-2000. Arch Sex Behav. 2001; 30(1):55-74. DOI: 10.1023/a:1026468707362. View

LEVI J, Thomson D, Sandeman T, Tattersall M, Raghavan D, Byrne M . A prospective study of cisplatin-based combination chemotherapy in advanced germ cell malignancy: role of maintenance and long-term follow-up. J Clin Oncol. 1988; 6(7):1154-60. DOI: 10.1200/JCO.1988.6.7.1154. View

LEVI J, Raghavan D, Harvey V, Thompson D, Sandeman T, Gill G . The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. Australasian Germ Cell Trial Group. J Clin Oncol. 1993; 11(7):1300-5. DOI: 10.1200/JCO.1993.11.7.1300. View

Horwich A, Oliver R, Wilkinson P, Mead G, Harland S, Cullen M . A medical research council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. MRC Testicular Tumour Working Party. Br J Cancer. 2000; 83(12):1623-9. PMC: 2363456. DOI: 10.1054/bjoc.2000.1498. View

Fossa S, Horwich A, Russell J, Roberts J, Cullen M, Hodson N . Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. J Clin Oncol. 1999; 17(4):1146. DOI: 10.1200/JCO.1999.17.4.1146. View

Dieckmann K, Bruggeboes B, Pichlmeier U, Kuster J, Mullerleile U, Bartels H . Adjuvant treatment of clinical stage I seminoma: is a single course of carboplatin sufficient?. Urology. 2000; 55(1):102-6. DOI: 10.1016/s0090-4295(99)00376-3. View

. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol. 1997; 15(2):594-603. DOI: 10.1200/JCO.1997.15.2.594. View

von der Maase H, Specht L, Jacobsen G, Jakobsen A, Madsen E, Pedersen M . Surveillance following orchidectomy for stage I seminoma of the testis. Eur J Cancer. 1993; 29A(14):1931-4. DOI: 10.1016/0959-8049(93)90446-m. View

Adami H, Bergstrom R, Mohner M, Zatonski W, Storm H, Ekbom A . Testicular cancer in nine northern European countries. Int J Cancer. 1994; 59(1):33-8. DOI: 10.1002/ijc.2910590108. View

10.

Jones W, Fossa S, Mead G, Roberts J, Sokal M, Horwich A . Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol. 2005; 23(6):1200-8. DOI: 10.1200/JCO.2005.08.003. View

11.

Bajorin D, Sarosdy M, Pfister D, Mazumdar M, Motzer R, Scher H . Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol. 1993; 11(4):598-606. DOI: 10.1200/JCO.1993.11.4.598. View

12.

Oliver R, Edmonds P, Ong J, Ostrowski M, Jackson A, Williams M . Pilot studies of 2 and 1 course carboplatin as adjuvant for stage I seminoma: should it be tested in a randomized trial against radiotherapy?. Int J Radiat Oncol Biol Phys. 1994; 29(1):3-8. DOI: 10.1016/0360-3016(94)90219-4. View

13.

de Wit R, Roberts J, Wilkinson P, de Mulder P, Mead G, Fossa S . Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer.... J Clin Oncol. 2001; 19(6):1629-40. DOI: 10.1200/JCO.2001.19.6.1629. View

14.

Dearnaley D, Huddart R, Horwich A . Regular review: Managing testicular cancer. BMJ. 2001; 322(7302):1583-8. PMC: 1120626. DOI: 10.1136/bmj.322.7302.1583. View

15.

Hay J, Duncan W, Kerr G . Subsequent malignancies in patients irradiated for testicular tumours. Br J Radiol. 1984; 57(679):597-602. DOI: 10.1259/0007-1285-57-679-597. View

16.

Dieckmann K, Albers P, Classen J, de Wit M, Pichlmeier U, Rick O . Late relapse of testicular germ cell neoplasms: a descriptive analysis of 122 cases. J Urol. 2005; 173(3):824-9. DOI: 10.1097/01.ju.0000154013.96349.36. View

17.

Samson M, Rivkin S, Jones S, COSTANZI J, LoBuglio A, Stephens R . Dose-response and dose-survival advantage for high versus low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer. A Southwest Oncology Group study. Cancer. 1984; 53(5):1029-35. DOI: 10.1002/1097-0142(19840301)53:5<1029::aid-cncr2820530503>3.0.co;2-z. View

18.

Einhorn L, Williams S, Troner M, Birch R, Greco F . The role of maintenance therapy in disseminated testicular cancer. N Engl J Med. 1981; 305(13):727-31. DOI: 10.1056/NEJM198109243051303. View

19.

Bosl G, Geller N, Bajorin D, Leitner S, Yagoda A, GOLBEY R . A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. J Clin Oncol. 1988; 6(8):1231-8. DOI: 10.1200/JCO.1988.6.8.1231. View

20.

Oliver R, Mason M, Mead G, von der Maase H, Rustin G, Joffe J . Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet. 2005; 366(9482):293-300. DOI: 10.1016/S0140-6736(05)66984-X. View